$ANAB
AnaptysBio Inc Stock $anab

$anab Overview Financials Valuation SEC Filings Company Website

2018 Q4 Form 10-Q Financial Statement

#000137005318000052 Filed on November 08, 2018

Income Statement

Concept	2018 Q4	2018 Q3	2017 Q3
Revenue	$0.00	$5.000M	$0.00
YoY Change	-100.0%		-100.0%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$3.740M	$4.000M	$2.390M
YoY Change	46.67%	67.36%	136.63%
% of Gross Profit
Research & Development	$15.92M	$17.88M	$6.697M
YoY Change	109.2%	167.03%	104.05%
% of Gross Profit
Depreciation & Amortization	$110.0K	$90.00K	$50.00K
YoY Change	175.0%	80.0%	-16.67%
% of Gross Profit
Operating Expenses	$19.66M	$21.89M	$9.087M
YoY Change	93.69%	140.86%	111.87%
Operating Profit	-$19.66M	-$16.89M	-$9.087M
YoY Change	174.97%	85.84%	745.3%
Interest Expense	$2.470M	$400.0K	$452.0K
YoY Change	111.11%	-11.5%	289.66%
% of Operating Profit
Other Income/Expense, Net	$10.00K	$929.0K	-$3.000K
YoY Change	-101.14%	-31066.67%	-92.5%
Pretax Income	-$17.19M	-$15.96M	-$9.090M
YoY Change	150.58%	75.56%	711.61%
Income Tax	-$190.0K	$0.00
% Of Pretax Income
Net Earnings	-$16.99M	-$15.96M	-$9.090M
YoY Change	147.67%	75.56%	715.25%
Net Earnings / Revenue		-319.16%
Basic Earnings Per Share	-$0.64	-$0.66	-$0.45
Diluted Earnings Per Share	-$0.64	-$0.66	-$0.45
COMMON SHARES
Basic Shares Outstanding	26.75M shares	24.04M shares	20.38M shares
Diluted Shares Outstanding			20.38M shares

Balance Sheet

Concept	2018 Q4	2018 Q3	2017 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments	$427.1M	$493.8M	$115.7M
YoY Change	71.93%	326.72%	145.69%
Cash & Equivalents	$113.6M	$293.4M	$26.67M
Short-Term Investments	$313.5M	$200.4M	$89.05M
Other Short-Term Assets	$7.000M	$4.000M	$3.100M
YoY Change	159.26%	29.03%	181.82%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets	$434.2M	$503.0M	$120.3M
YoY Change	71.83%	318.05%	129.63%
LONG-TERM ASSETS
Property, Plant & Equipment	$1.445M	$1.344M	$513.0K
YoY Change	117.29%	161.99%	28.25%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments	$73.10M	$18.60M	$1.000M
YoY Change	-3.69%	1760.0%
Other Assets	$148.0K	$79.00K	$100.0K
YoY Change	221.74%	-21.0%	-96.77%
Total Long-Term Assets	$74.78M	$20.10M	$1.618M
YoY Change	-2.46%	1142.21%	-52.41%
TOTAL ASSETS
Total Short-Term Assets	$434.2M	$503.0M	$120.3M
Total Long-Term Assets	$74.78M	$20.10M	$1.618M
Total Assets	$509.0M	$523.1M	$121.9M
YoY Change	54.54%	328.98%	118.54%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$5.443M	$6.180M	$2.557M
YoY Change	134.31%	141.69%	82.64%
Accrued Expenses	$8.761M	$7.145M	$3.604M
YoY Change	79.71%	98.25%	20.13%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$7.600M	$7.500M	$5.000M
YoY Change	10.14%	50.0%	233.33%
Total Short-Term Liabilities	$21.84M	$20.87M	$11.17M
YoY Change	54.98%	86.8%	48.99%
LONG-TERM LIABILITIES
Long-Term Debt	$600.0K	$2.400M	$9.300M
YoY Change	-92.11%	-74.19%	173.53%
Other Long-Term Liabilities	$796.0K	$200.0K	$100.0K
YoY Change	696.0%	100.0%	-92.86%
Total Long-Term Liabilities	$796.0K	$2.600M	$9.400M
YoY Change	-89.66%	-72.34%	95.83%
TOTAL LIABILITIES
Total Short-Term Liabilities	$21.84M	$20.87M	$11.17M
Total Long-Term Liabilities	$796.0K	$2.600M	$9.400M
Total Liabilities	$22.63M	$23.40M	$20.60M
YoY Change	3.82%	13.59%	67.48%
SHAREHOLDERS EQUITY
Retained Earnings	-$146.7M	-$129.7M	-$78.20M
YoY Change	72.51%	65.85%
Common Stock	$27.00K	$27.00K	$20.00K
YoY Change	12.5%	35.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$486.4M	$499.7M	$101.4M
YoY Change
Total Liabilities & Shareholders Equity	$509.0M	$523.1M	$121.9M
YoY Change	54.54%	328.98%	118.54%

Cashflow Statement

Concept	2018 Q4	2018 Q3	2017 Q3
OPERATING ACTIVITIES
Net Income	-$16.99M	-$15.96M	-$9.090M
YoY Change	147.67%	75.56%	715.25%
Depreciation, Depletion And Amortization	$110.0K	$90.00K	$50.00K
YoY Change	175.0%	80.0%	-16.67%
Cash From Operating Activities	-$12.29M	-$14.86M	-$3.890M
YoY Change	155.51%	282.01%	26.71%
INVESTING ACTIVITIES
Capital Expenditures	-$200.0K	-$320.0K	-$20.00K
YoY Change	66.67%	1500.0%
Acquisitions
YoY Change
Other Investing Activities	-$166.0M	$24.94M	-$490.0K
YoY Change	8.51%	-5189.8%
Cash From Investing Activities	-$166.1M	$24.62M	-$490.0K
YoY Change	8.55%	-5124.49%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net		$227.5M
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-1.380M	226.6M	300.0K
YoY Change	-100.65%	75433.33%	-178.95%
NET CHANGE
Cash From Operating Activities	-12.29M	-14.86M	-3.890M
Cash From Investing Activities	-166.1M	24.62M	-490.0K
Cash From Financing Activities	-1.380M	226.6M	300.0K
Net Change In Cash	-179.8M	236.4M	-4.080M
YoY Change	-429.88%	-5893.14%	18.26%
FREE CASH FLOW
Cash From Operating Activities	-$12.29M	-$14.86M	-$3.890M
Capital Expenditures	-$200.0K	-$320.0K	-$20.00K
Free Cash Flow	-$12.09M	-$14.54M	-$3.870M
YoY Change	157.78%	275.71%	26.06%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2017Q4	anab	Accrued Research And Contract Manufacturing Expenses Current AccruedResearchAndContractManufacturingExpensesCurrent	2961000	USD
CY2018Q3	anab	Accrued Research And Contract Manufacturing Expenses Current AccruedResearchAndContractManufacturingExpensesCurrent	4196000	USD
CY2018Q3	anab	Employee And Nonemployee Service Sharebased Compensation Nonvested Awards Compensation Not Yet Recognized Stock Options EmployeeAndNonemployeeServiceSharebasedCompensationNonvestedAwardsCompensationNotYetRecognizedStockOptions	27800000	USD
	anab	Payments For Proceeds From Stock Issuance Costs PaymentsForProceedsFromStockIssuanceCosts	1497000	USD
	anab	Payments For Proceeds From Stock Issuance Costs PaymentsForProceedsFromStockIssuanceCosts	-46000	USD
CY2017Q4	anab	Research And Development Tax Incentive Credit Receivable Current ResearchAndDevelopmentTaxIncentiveCreditReceivableCurrent	1601000	USD
CY2018Q3	anab	Research And Development Tax Incentive Credit Receivable Current ResearchAndDevelopmentTaxIncentiveCreditReceivableCurrent	200000	USD
	anab	Research And Development Tax Incentive Credit Received During Period ResearchAndDevelopmentTaxIncentiveCreditReceivedDuringPeriod	4600000	USD
CY2018Q3	anab	Research And Development Tax Incentive Credit Receivable Current ResearchAndDevelopmentTaxIncentiveCreditReceivableCurrent	173000	USD
	anab	Research And Development Tax Incentive Credit Received During Period ResearchAndDevelopmentTaxIncentiveCreditReceivedDuringPeriod	1500000	USD
	anab	Revenue Recognition Milestone Method Milestones Achieved During The Period RevenueRecognitionMilestoneMethodMilestonesAchievedDuringThePeriod	2	milestone
CY2017Q3	anab	Sharebased Compensation And Issuance Of Stock And Warrants For Services Or Claims SharebasedCompensationAndIssuanceOfStockAndWarrantsForServicesOrClaims	942000	USD
	anab	Sharebased Compensation And Issuance Of Stock And Warrants For Services Or Claims SharebasedCompensationAndIssuanceOfStockAndWarrantsForServicesOrClaims	3246000	USD
CY2018Q3	anab	Sharebased Compensation And Issuance Of Stock And Warrants For Services Or Claims SharebasedCompensationAndIssuanceOfStockAndWarrantsForServicesOrClaims	2532000	USD
	anab	Sharebased Compensation And Issuance Of Stock And Warrants For Services Or Claims SharebasedCompensationAndIssuanceOfStockAndWarrantsForServicesOrClaims	7340000	USD
	anab	Stock Issuance Costs Incurred During Noncash Transaction StockIssuanceCostsIncurredDuringNoncashTransaction	215000	USD
	anab	Stock Issuance Costs Incurred During Noncash Transaction StockIssuanceCostsIncurredDuringNoncashTransaction	241000	USD
	anab	Transfer Of Warrants To Equity TransferOfWarrantsToEquity	4607000	USD
	anab	Transfer Of Warrants To Equity TransferOfWarrantsToEquity	0	USD
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2018
	dei	Document Period End Date DocumentPeriodEndDate	2018-09-30
	dei	Document Type DocumentType	10-Q
	dei	Entity Central Index Key EntityCentralIndexKey	0001370053
CY2018Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	26751578	shares
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
	dei	Entity Ex Transition Period EntityExTransitionPeriod	true
	dei	Entity Filer Category EntityFilerCategory	Accelerated Filer
	dei	Entity Registrant Name EntityRegistrantName	ANAPTYSBIO INC
	dei	Entity Small Business EntitySmallBusiness	false
CY2017Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	2323000	USD
CY2018Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	6180000	USD
CY2017Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	4875000	USD
CY2018Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	7145000	USD
CY2017Q4	us-gaap	Accrued Rent Noncurrent AccruedRentNoncurrent	140000	USD
CY2018Q3	us-gaap	Accrued Rent Noncurrent AccruedRentNoncurrent	162000	USD
CY2017Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	3978000	USD
CY2018Q3	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	4092000	USD
CY2017Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-426000	USD
CY2018Q3	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-541000	USD
CY2017Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	393017000	USD
CY2018Q3	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	629887000	USD
CY2017Q3	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	1755000	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	2092000	shares
CY2018Q3	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	2402000	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	2517000	shares
CY2017Q4	us-gaap	Assets Assets	329364000	USD
CY2018Q3	us-gaap	Assets Assets	523121000	USD
CY2017Q4	us-gaap	Assets Current AssetsCurrent	252696000	USD
CY2018Q3	us-gaap	Assets Current AssetsCurrent	503022000	USD
CY2018Q3	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	1000	USD
CY2018Q3	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	542000	USD
CY2018Q3	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	221879000	USD
	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	160000	USD
	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	12000	USD
CY2018Q3	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	221338000	USD
CY2017Q4	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	167218000	USD
CY2018Q3	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	200406000	USD
CY2017Q4	us-gaap	Available For Sale Securities Debt Securities Noncurrent AvailableForSaleSecuritiesDebtSecuritiesNoncurrent	75897000	USD
CY2018Q3	us-gaap	Available For Sale Securities Debt Securities Noncurrent AvailableForSaleSecuritiesDebtSecuritiesNoncurrent	18616000	USD
CY2017Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	81189000	USD
CY2018Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	293408000	USD
CY2016Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	51292000	USD
CY2017Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	26729000	USD
CY2017Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	81249000	USD
CY2018Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	293468000	USD
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-24563000	USD
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	212219000	USD
CY2018Q3	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	4802496	shares
CY2017Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2018Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2017Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2017Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	500000000	shares
CY2018Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	500000000	shares
CY2017Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	500000000	shares
CY2017Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	23791000	shares
CY2018Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	26748713	shares
CY2018Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	26749000	shares
CY2017Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	23791000	shares
CY2018Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	26748713	shares
CY2018Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	26749000	shares
CY2017Q4	us-gaap	Common Stock Value CommonStockValue	24000	USD
CY2018Q3	us-gaap	Common Stock Value CommonStockValue	27000	USD
CY2017Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-9074000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-23252000	USD
CY2018Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-15822000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-44777000	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	136000	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	209000	USD
CY2017Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.45
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-1.24
CY2018Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.66
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-1.86
CY2017Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	1588000	USD
CY2018Q3	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	2176000	USD
CY2017Q3	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	0	USD
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	1366000	USD
CY2018Q3	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	0	USD
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	0	USD
CY2017Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2390000	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	6793000	USD
CY2018Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	4004000	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	11783000	USD
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	1081000	USD
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	5946000	USD
	us-gaap	Increase Decrease In Contract With Customer Asset IncreaseDecreaseInContractWithCustomerAsset	-1225000	USD
	us-gaap	Increase Decrease In Contract With Customer Asset IncreaseDecreaseInContractWithCustomerAsset	5000000	USD
	us-gaap	Increase Decrease In Income Taxes Receivable IncreaseDecreaseInIncomeTaxesReceivable	-2632000	USD
	us-gaap	Increase Decrease In Income Taxes Receivable IncreaseDecreaseInIncomeTaxesReceivable	-1428000	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	1581000	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	1403000	USD
CY2017Q3	us-gaap	Interest Expense InterestExpense	452000	USD
	us-gaap	Interest Expense InterestExpense	1319000	USD
CY2018Q3	us-gaap	Interest Expense InterestExpense	400000	USD
	us-gaap	Interest Expense InterestExpense	1287000	USD
CY2017Q3	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	358000	USD
	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	762000	USD
CY2018Q3	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	1369000	USD
	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	3851000	USD
	us-gaap	Interest Paid Net InterestPaidNet	762000	USD
	us-gaap	Interest Paid Net InterestPaidNet	835000	USD
CY2017Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	329364000	USD
CY2018Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	523121000	USD
CY2017Q4	us-gaap	Liabilities Current LiabilitiesCurrent	14090000	USD
CY2018Q3	us-gaap	Liabilities Current LiabilitiesCurrent	20873000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	80066000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	224736000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-90001000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	23699000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-14628000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-36216000	USD
CY2017Q3	us-gaap	Net Income Loss NetIncomeLoss	-9090000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-23209000	USD
CY2018Q3	us-gaap	Net Income Loss NetIncomeLoss	-15958000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-44662000	USD
CY2017Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-3000	USD
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-1579000	USD
CY2018Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	929000	USD
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	2397000	USD
CY2017Q4	us-gaap	Notes Payable Current NotesPayableCurrent	6875000	USD
CY2018Q3	us-gaap	Notes Payable Current NotesPayableCurrent	7500000	USD
CY2017Q4	us-gaap	Notes Payable To Bank Noncurrent NotesPayableToBankNoncurrent	7553000	USD
CY2018Q3	us-gaap	Notes Payable To Bank Noncurrent NotesPayableToBankNoncurrent	2409000	USD
	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	1	segment
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	814000	USD
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	2138000	USD
CY2017Q3	us-gaap	Operating Expenses OperatingExpenses	9087000	USD
	us-gaap	Operating Expenses OperatingExpenses	28630000	USD
CY2018Q3	us-gaap	Operating Expenses OperatingExpenses	21887000	USD
	us-gaap	Operating Expenses OperatingExpenses	52059000	USD
CY2017Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-9087000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-21630000	USD
CY2018Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-16887000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-47059000	USD
CY2018Q3	us-gaap	Operating Leases Future Minimum Payments Due OperatingLeasesFutureMinimumPaymentsDue	2833000	USD
CY2018Q3	us-gaap	Operating Leases Future Minimum Payments Due In Five Years OperatingLeasesFutureMinimumPaymentsDueInFiveYears	0	USD
CY2018Q3	us-gaap	Operating Leases Future Minimum Payments Due In Four Years OperatingLeasesFutureMinimumPaymentsDueInFourYears	726000	USD
CY2018Q3	us-gaap	Operating Leases Future Minimum Payments Due In Three Years OperatingLeasesFutureMinimumPaymentsDueInThreeYears	968000	USD
CY2018Q3	us-gaap	Operating Leases Future Minimum Payments Due In Two Years OperatingLeasesFutureMinimumPaymentsDueInTwoYears	938000	USD
CY2018Q3	us-gaap	Operating Leases Future Minimum Payments Due Thereafter OperatingLeasesFutureMinimumPaymentsDueThereafter	0	USD
CY2018Q3	us-gaap	Operating Leases Future Minimum Payments Remainder Of Fiscal Year OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear	201000	USD
CY2017Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	326000	USD
CY2018Q3	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	773000	USD
CY2017Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	46000	USD
CY2018Q3	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	79000	USD
CY2017Q3	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	16000	USD
	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-43000	USD
CY2018Q3	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	136000	USD
	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-115000	USD
CY2017Q3	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	16000	USD
	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-43000	USD
CY2018Q3	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	136000	USD
	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-115000	USD
CY2017Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	17000	USD
CY2018Q3	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	48000	USD
	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-460000	USD
	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-481000	USD
CY2017Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	91000	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	344000	USD
CY2018Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-40000	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-167000	USD
	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	110701000	USD
	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	123995000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	166000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	857000	USD
CY2017Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2018Q3	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2017Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2017Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	0	shares
CY2018Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2017Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2017Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	2100000	USD
CY2018Q3	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2017Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2018Q3	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2017Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2018Q3	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2017Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	2688000	USD
CY2018Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	4035000	USD
CY2017Q4	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	194700000	USD
CY2018Q3	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	227500000	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	80213000	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	227476000	USD
	us-gaap	Proceeds From Sale And Maturity Of Available For Sale Securities ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities	20866000	USD
	us-gaap	Proceeds From Sale And Maturity Of Available For Sale Securities ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities	148551000	USD
	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	536000	USD
	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	76000	USD
CY2017Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	4643000	USD
CY2018Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	17883000	USD
CY2018Q3	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	5436000	USD
CY2017Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	665000	USD
CY2018Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1344000	USD
CY2017Q4	us-gaap	Receivables Net Current ReceivablesNetCurrent	0	USD
CY2018Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	25.57
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	5.21
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	100.98
CY2018Q3	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	118779000	USD
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P6Y3M09D
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P7Y3M1D
CY2017Q4	us-gaap	Shares Issued Price Per Share SharesIssuedPricePerShare	68.50
CY2018Q3	us-gaap	Shares Issued Price Per Share SharesIssuedPricePerShare	94.46
CY2017Q4	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	3000000	shares
CY2018Q3	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	2530000	shares
	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	410551	shares
CY2017Q4	us-gaap	Stockholders Equity StockholdersEquity	307581000	USD
CY2018Q3	us-gaap	Stockholders Equity StockholdersEquity	499677000	USD
CY2018Q3	us-gaap	Receivables Net Current ReceivablesNetCurrent	5000000	USD
	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	0	USD
	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	5000000	USD
CY2017Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	6697000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	21837000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	40276000	USD
CY2017Q4	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	60000	USD
CY2018Q3	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	60000	USD
CY2017Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-85034000	USD
CY2018Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-129696000	USD
CY2017Q3	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	0	USD
	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	7000000	USD
CY2018Q3	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	5000000	USD
	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	5000000	USD
CY2018Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	1330540	shares
CY2018Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	10.62
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod	46520	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice	49.68
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	1061106	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	339557	shares
CY2018Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	173085000	USD
CY2017Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	2425903	shares
CY2018Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	2308389	shares
CY2017Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	12.03
CY2017Q1	us-gaap	Stockholders Equity Note Stock Split Conversion Ratio1 StockholdersEquityNoteStockSplitConversionRatio1	0.1429
	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments	-16000	USD
	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments	555000	USD
CY2017Q3	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	20382000	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	18668000	shares
CY2018Q3	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	24146000	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	23961000	shares
	us-gaap	Nature Of Operations NatureOfOperations	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Description of the Business </font></div><div style="line-height:120%;padding-top:8px;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">AnaptysBio, Inc. (“we,” “us,” “our,” or the “Company”) was incorporated in the state of Delaware in November 2005. We are a biotechnology company developing first-in-class antibody product candidates focused on unmet medical needs in inflammation. We develop our product candidates using our proprietary, antibody discovery technology platform, which is designed to replicate, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">in vitro</font><font style="font-family:inherit;font-size:10pt;">, the natural process of antibody generation. We currently generate revenue from milestones achieved under our collaborative research and development arrangements. </font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Since our inception, we have devoted our primary effort to raising capital and research and development activities. Our financial support has been provided primarily from the sale of our common and preferred stock, as well as through funds received under our collaborative research and development agreements, proceeds from our Term Loans as discussed in Note 5 below, and the issuance of convertible debt. Going forward, as we continue our expansion, we may seek additional financing and/or strategic investments. However, there can be no assurance that any additional financing or strategic investments will be available to us on acceptable terms, if at all. If events or circumstances occur such that we do not obtain additional funding, we will most likely be required to reduce our plans and/or certain discretionary spending, which could have a material adverse effect on our ability to achieve our intended business objectives. Management believes its currently available resources will provide sufficient funds to enable the Company to meet its operating plans for at least the next twelve months. The accompanying consolidated financial statements do not include any adjustments that might be necessary if we are unable to continue as a going concern.</font></div><div style="line-height:120%;padding-top:24px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Public Offerings and Related Transactions</font></div><div style="line-height:120%;padding-top:24px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;background-color:#ffffff;font-style:italic;font-weight:bold;">Initial Public Offering</font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;background-color:#ffffff;">On January 31, 2017, we completed an initial public offering, or IPO, selling </font><font style="font-family:inherit;font-size:10pt;background-color:#ffffff;">5,750,000</font><font style="font-family:inherit;font-size:10pt;background-color:#ffffff;"> shares of common stock at </font><font style="font-family:inherit;font-size:10pt;background-color:#ffffff;">$15.00</font><font style="font-family:inherit;font-size:10pt;background-color:#ffffff;"> per share. Proceeds from our initial public offering net of underwriting discounts and commissions were </font><font style="font-family:inherit;font-size:10pt;background-color:#ffffff;">$80.2 million</font><font style="font-family:inherit;font-size:10pt;background-color:#ffffff;">.</font></div><div style="line-height:120%;padding-top:16px;text-align:left;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;background-color:#ffffff;">In addition, each of the following occurred in connection with the completion of the IPO on January 31, 2017:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:66px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:inherit;font-size:10pt;">•</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the conversion of all outstanding shares of convertible preferred stock into </font><font style="font-family:inherit;font-size:10pt;">11,520,698</font><font style="font-family:inherit;font-size:10pt;"> shares of common stock; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:65px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:32px;"><font style="font-family:inherit;font-size:10pt;">•</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the conversion of warrants to purchase </font><font style="font-family:inherit;font-size:10pt;">377,195</font><font style="font-family:inherit;font-size:10pt;"> shares of convertible preferred stock into warrants to purchase </font><font style="font-family:inherit;font-size:10pt;">377,195</font><font style="font-family:inherit;font-size:10pt;"> shares of common stock and the resultant reclassification of the warrant liability to additional paid-in capital.</font></div></td></tr></table><div style="line-height:120%;padding-top:24px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Reverse Stock Split </font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On January 13, 2017, we amended and restated our certificate of incorporation to effect a </font><font style="font-family:inherit;font-size:10pt;">one</font><font style="font-family:inherit;font-size:10pt;"> for </font><font style="font-family:inherit;font-size:10pt;">seven</font><font style="font-family:inherit;font-size:10pt;"> reverse stock split of every outstanding share of our preferred and common stock. The financial statements and accompanying footnotes have been retroactively restated to reflect the reverse stock split. </font></div><div style="line-height:120%;padding-top:24px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Follow-on Public Offerings </font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On October 17, 2017, we completed an underwritten public offering selling </font><font style="font-family:inherit;font-size:10pt;">3,000,000</font><font style="font-family:inherit;font-size:10pt;"> shares of common stock. All shares were offered by us at a price to the public of </font><font style="font-family:inherit;font-size:10pt;">$68.50</font><font style="font-family:inherit;font-size:10pt;"> per share. The aggregate net proceeds received by us from the offering were </font><font style="font-family:inherit;font-size:10pt;">$194.7 million</font><font style="font-family:inherit;font-size:10pt;">, net of underwriting discounts and commissions. As part of the underwritten public offering, on November 14, 2017, the underwriters exercised an additional </font><font style="font-family:inherit;font-size:10pt;">271,380</font><font style="font-family:inherit;font-size:10pt;"> shares of common stock at a discounted price to the public of </font><font style="font-family:inherit;font-size:10pt;">$68.50</font><font style="font-family:inherit;font-size:10pt;"> per share for aggregate net proceeds of </font><font style="font-family:inherit;font-size:10pt;">$17.6 million</font><font style="font-family:inherit;font-size:10pt;">, net of underwriting discounts and commissions.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On September 28, 2018, we completed an underwritten public offering of </font><font style="font-family:inherit;font-size:10pt;">2,530,000</font><font style="font-family:inherit;font-size:10pt;"> shares of common stock, which included the exercise of the underwriters’ option to purchase an additional </font><font style="font-family:inherit;font-size:10pt;">330,000</font><font style="font-family:inherit;font-size:10pt;"> shares of common stock. All shares were offered by us at a price to the public of </font><font style="font-family:inherit;font-size:10pt;">$94.46</font><font style="font-family:inherit;font-size:10pt;"> per share. The aggregate net proceeds received by us from the offering were </font><font style="font-family:inherit;font-size:10pt;">$227.5 million</font><font style="font-family:inherit;font-size:10pt;">, net of underwriting discounts and commissions.</font></div></div>
	us-gaap	Use Of Estimates UseOfEstimates	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:24px;text-align:left;padding-left:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Use of Estimates </font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The preparation of the accompanying consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements and reported amounts of revenues and expenses during the reporting periods. Actual results could differ from those estimates. We base our estimates and assumptions on historical experience when available and on various factors that we believe to be reasonable under the circumstances. We evaluate our estimates and assumptions on an ongoing basis. Our actual results could differ from these estimates under different assumptions or conditions.</font></div></div>

Files In Submission

Name	View Source	Status
0001370053-18-000052-index-headers.html	Edgar Link	pending
0001370053-18-000052-index.html	Edgar Link	pending
0001370053-18-000052.txt	Edgar Link	pending
0001370053-18-000052-xbrl.zip	Edgar Link	pending
anab-20180930.xml	Edgar Link	completed
anab-20180930.xsd	Edgar Link	pending
anab-20180930_cal.xml	Edgar Link	unprocessable
anab-20180930_def.xml	Edgar Link	unprocessable
anab-20180930_lab.xml	Edgar Link	unprocessable
anab-20180930_pre.xml	Edgar Link	unprocessable
anab-93018x10q.htm	Edgar Link	pending
anab-93018x10qxexx311.htm	Edgar Link	pending
anab-93018x10qxexx312.htm	Edgar Link	pending
anab-93018x10qxexx321.htm	Edgar Link	pending
anab-93018x10qxexx322.htm	Edgar Link	pending
employementagreementloumeau.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
pipelinechart11518.jpg	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$ANAB
AnaptysBio Inc Stock $anab

2018 Q4 Form 10-Q Financial Statement

#000137005318000052 Filed on November 08, 2018

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ANAB AnaptysBio Inc Stock $anab

2018 Q4 Form 10-Q Financial Statement

#000137005318000052 Filed on November 08, 2018

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ANAB
AnaptysBio Inc Stock $anab